PaperPhase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma
References (16)
- et al.
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma
J Clin Oncol
(1989) - et al.
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma
Sem Oncol
(1990) - et al.
Reporting results of cancer treatment
Cancer
(1981) - et al.
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma
J Clin Oncol
(1990) - et al.
Interferon alfa-2a and 5-fluorouracil for advanced colorectal carcinoma: assessment of activity and toxicity
Cancer
(1990) - et al.
Phase II trial of 5 fluourouracil (5 FU) and recombinant alpha interferon (R alpha-IFN) (Intron AR) in metastatic, previously untreated colorectal cancer (CRC)
ASCO
(1991) - et al.
Phase II trial of 5 fluorouracil (5 FU) and recombinant interferon-alpha-2a (IFN) in advanced colorectal cancer
ASCO
(1991) - et al.
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an eastern cooperative oncology group study
J Clin Oncol
(1991)
There are more references available in the full text version of this article.
Cited by (15)
Different dose regimens of 5-fluorouracil and interferon-α in patients with metastatic colorectal carcinoma
1995, European Journal of CancerFailure to increase 5-fluorouracil activity with interferon-α2a in the treatment of advanced colorectal cancer
1995, European Journal of CancerTreatment of colorectal cancer metastasis: The role of chemotherapy
2004, Cancer and Metastasis ReviewsA phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
2002, American Journal of Clinical Oncology: Cancer Clinical TrialsPotential of interferon-α in solid tumours: Part 2
2002, BioDrugs
Copyright © 1992 Published by Elsevier Ltd.